Key result
Home-based peritoneal dialysis proves non-inferior to in-centre haemodialysis for kidney disease burden.
Why the study?
Little is known about the comparative impact of haemodialysis and peritoneal dialysis on health-related quality of life.
Does home-based peritoneal dialysis improve the burden of kidney disease compared to conventional in-centre haemodialysis in newly diagnosed kidney failure patients?
RCT (n=1,082)
1:1
Yes
Does home-based peritoneal dialysis improve the burden of kidney disease compared to conventional in-centre haemodialysis in newly diagnosed kidney failure patients?
Effect estimate: GM ratio 1.059 (95% CI 0.908-1.234)
Absolute Event Rate: 2.61% vs 2.58%
Home-based peritoneal dialysis is non-inferior to conventional in-centre haemodialysis regarding the patient-reported burden of kidney disease over 48 weeks, though it may be associated with more adverse events.
Supports home peritoneal dialysis as noninferior for patient-reported burden; extends randomized evidence for modality choice in kidney failure.
BACKGROUND: Little is known about the impact of haemodialysis (HD) and peritoneal dialysis (PD) on health-related quality of life (HRQoL). We compared HRQoL between conventional in-centre HD and home-based PD in 1082 newly diagnosed kidney failure patients. METHODS: ) requiring maintenance dialysis from 36 sites in China randomised 1:1 to receive PD or conventional in-centre HD. The primary outcome was the 'Burden of Kidney Disease' assessed using the Kidney Disease Quality of Life-Short Form (KDQoL-SF) survey over 48 weeks and the main secondary outcomes were the remaining scales of KDQoL-SF and all-cause mortality. The effect of PD versus HD on the primary outcome was compared by their geometric mean (GM) ratio, and non-inferiority was defined by the lower bound of a one-sided 95% confidence interval (CI) >0.9. RESULTS: A total of 725 subjects completed the trial per protocol (395 PD and 330 HD, mean age 49.8 (standard deviation (SD) 14.4) years, 41.4% women). For the primary outcome, the mean (SD) change in 'Burden of Kidney Disease' over 48 weeks was 2.61 (1.27) in PD group and 2.58 (1.35) in HD group, and the GM ratio (95% CI) was 1.059 (0.908-1.234), exceeding the limit for non-inferiority. For the secondary outcomes, the PD and HD groups were similar in all scales. There were 17 and 31 deaths in PD and HD groups, respectively. Patients receiving PD had more adverse events, adverse event leading to hospitalisation and serious adverse events compared to those allocated to HD, but adverse events leading to death and discontinuation of the trial were not different between PD and HD. CONCLUSIONS: In this trial, PD may be non-inferior to HD on the 'Burden of Kidney Disease' among Chinese kidney failure patients who are of younger age and have lower comorbidity after 48 weeks' follow-up.
No takes yet. Share an insight, caveat, or question.
Li et al. (2022) conducted an RCT in Kidney failure requiring maintenance dialysis (n=1,082). Peritoneal dialysis (PD) vs. Conventional in-centre haemodialysis (HD) was evaluated on Burden of Kidney Disease assessed using the KDQoL-SF survey (GM ratio 1.059, 95% CI 0.908-1.234). Home-based peritoneal dialysis was non-inferior to conventional in-centre haemodialysis for the Burden of Kidney Disease score over 48 weeks (GM ratio 1.059; 95% CI 0.908-1.234).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: